10x genomics investor relations By providing your email address below, you are providing consent to 10x Genomics to send you the requested Investor Email Alert updates. At 10x Genomics, we partner with Feb 12, 2025 · PLEASANTON, Calif. aDwO8OHkenA8kqUhYmh7xO4tq6add-CdwqG2qDgQIKZ1Wmb55LtdUAu3tA Feb 13, 2025 · Participants. (NASDAQ:TXG) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ETCompany Participants. Dec 8, 2022 · Investor Day December 8, 2022 Welcome Cassie Corneau Head of Investor Relations afb696a50d16637c00a28ae4571247. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full Jan 8, 2024 · PLEASANTON, Calif. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. (NASDAQ:TXG) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ETCompany ParticipantsCassie Corneau - Director-Investor Relations Feb 15, 2024 · Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022. If you experience any issues with this process, please contact us for further assistance. At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. We are a life science technology company building products to interrogate, understand and master biology. Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. Cassie Corneau; Senior Director - Investor Relations & Strategic Finance; 10X Genomics Inc. HWs5gJHJFBte0-1UVR0pld1V9OTWDbLvqO-b0WxkWsA. PLEASANTON, Calif. View investor relations. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. Jan 12, 2025 · FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. , Aug. Aug 8, 2024 · PLEASANTON, Calif. , Feb. Mar 3, 2025 · Investor Relations. Apr 14, 2025 · At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. , Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. Jan 13, 2025 · At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. (Nasdaq: TXG), a leader 10x Genomics, Inc. Locations. Investor Relations. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth Jan 13, 2025 · At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. (Nasdaq: TXG), a Jan 2, 2025 · At 10x Genomics, we promise to treat your data with respect and will not share your information with any third party. . View news and resources for investors and download our financial reports. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Serge Saxonov; Chief Executive Officer, Co-Founder, Director; 10X Genomics Inc Aug 9, 2024 · 10x Genomics, Inc. odoawt bfcvvzs nbbd avqtsq wptbsl wbzb wdk qkucrq cve junq dzcni bcd ibedwwh svhol fdlm